Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Comment by Steveminon Jan 03, 2021 5:23pm
138 Views
Post# 32212344

RE:RE:RE:RE:RE:RE:Smart Money Accumulating ?

RE:RE:RE:RE:RE:RE:Smart Money Accumulating ? Bullknit - I would have never invested in Inmed if I didn't believe in the science. I aways felt that what we were being told was legit and had potential. My big issue is with Adams. He has really slow rolled this company while being less than transparent along the way. It is not acceptable to ignore investors calls and emails and delaying literally every milestone along the way.

This coming June will mark his 5 year anniversary with the company. Honestly, the biosynthesis manufacturing system isn't anywhere near where it should be. I have been told that the relationship with Almac is basically over which is why they decided to pivot to Baymedica. This - in some peoples opinion - is a "hail mary" attempt to see if there's anything viable about the system. Why else would you need Baymedica?? Remember, Adams has been adamant that he wanted to keep 100% of the rights of biosynthesis program, now all the sudden he is interested in a licensing deal? Goes against everything he has said all along.

I spoke to some people who are very intelligent in this industry and asked them "why is it that when the subject of cannabinoid biosynthesis comes up, no one ever mentions Inmed?" Their answers were all the same - "Inmed's IP isn't strong and they have yet to offer any insight as to the current viability". Remember, these are the same people who are seeing the PCT'S as they become available and are not worried that Inmed will be a viable competitor yet.  That may change, but that's how they are viewed by their peers currently.

My fear is thats why Dr. Hossain left - he knew they hit a brick wall. Thats why Blacher and Bott left as well. Adams has only filled positions with his buddies from other companies mostly. Something just doesn't smell right.
<< Previous
Bullboard Posts
Next >>